Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORIOSA maintenance study of mirvetuximab soravtansine + bevacizumab versus bevacizumab alone in FRα-high recurrent platinum-sensitive ovarian cancer
2022-501606-35-01Phase 4Authorised
- Sponsor
- AbbVie Inc.
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 23
01
Overview
Phase 4, randomised, open-label trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Mirvetuximab soravtansine + bevacizumab maintenance with Bevacizumab maintenance (2 arms). Primary endpoints: Progression-free survival and Progression-free survival by investigator. Planned start Feb 2024; status: authorised.
02
Drugs
mirvetuximab soravtansinebevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2022-501606-35-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501606-35-01.